(S1 (S (S (NP (NN Hyperforin)) (VP (VP (VBZ blocks) (NP (NP (NN neutrophil) (NN activation)) (PP (IN of) (NP (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (NN motility)) (CC and) (NP (NN recruitment)))))) (, ,) (CC and) (VP (VBZ restrains) (NP (NP (JJ inflammation-triggered) (NN angiogenesis)) (CC and) (NP (NN lung) (NN fibrosis)))))) (. .)))
(S1 (S (NP (NP (NP (NN Hyperforin)) (PRN (-LRB- -LRB-) (NP (NN Hyp)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN polyphenol-derivative)) (PP (IN of) (NP (JJ St)))) (. .))))
(S1 (S (S (NP (NP (NP (NN John) (POS 's)) (NN wort)) (PRN (-LRB- -LRB-) (NP (NN Hypericum) (NN perforatum)) (-RRB- -RRB-)) (, ,)) (VP (VBZ has) (VP (VBN emerged) (PP (IN as) (NP (NP (JJ key) (NN player)) (PP (CONJP (RB not) (RB only)) (PP (IN in) (NP (NP (DT the) (JJ antidepressant) (NN activity)) (PP (IN of) (NP (DT the) (NN plant))))) (CONJP (CC but) (RB also)) (PP (IN as) (NP (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NNS bacteria) (NP (NP (NN lymphocyte)) (CC and) (NP (NN tumor) (NN cell) (NN proliferation)))))) (, ,) (CC and) (NP (NN matrix) (NNS proteinases)))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD tested) (SBAR (IN whether) (S (S (VP (CONJP (RB as) (RB well) (IN as)) (VP (VBG inhibiting) (NP (NP (NP (NN leukocyte) (NN elastase)) (PRN (-LRB- -LRB-) (NP (NN LE)) (-RRB- -RRB-))) (NN activity))))) (, ,) (NP (NN Hyp)) (VP (MD might) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG containing) (NP (CC both) (NP (JJ polymorphonuclear) (NP (NP (NN neutrophil)) (PRN (-LRB- -LRB-) (NP (NN PMN)) (-RRB- -RRB-))) (NN leukocyte) (NN recruitment)) (CC and) (NP (JJ unfavorable) (JJ eventual) (NN tissue) (NNS responses))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (, ,) (PP (IN without) (S (VP (VBG affecting) (NP (NP (ADJP (FW in) (FW vitro)) (JJ human) (NN PMN) (NN viability)) (CC and) (NP (NN chemokine-receptor) (NN expression)))))) (, ,) (NP (NP (NN Hyp)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (JJ stable) (NN dicyclohexylammonium) (NN salt))) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (VB inhibit) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (NP (NP (PRP$ their) (NN chemotaxis)) (CC and) (NP (NP (NN chemoinvasion)) (PRN (-LRB- -LRB-) (NP (NP (CD IC50=1) (NN microM)) (PP (IN for) (NP (DT both)))) (-RRB- -RRB-))))))))))))) (: ;) (S (NP (DT this) (NN effect)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (VBN reduced) (NN expression)) (PP (IN of) (NP (DT the) (NN adhesion) (NN molecule) (NN CD11b))) (PP (IN by) (NP (JJ formyl-Met-Leu-Phe-stimulated) (NNS neutrophils)))) (CC and) (NP (NP (NN block)) (PP (IN of) (NP (NP (JJ LE-triggered) (NN activation)) (PP (IN of) (NP (DT the) (NN gelatinase) (NN matrix) (NN metalloproteinase-9))))))))))) (. .)))
(S1 (S (S (NP (JJ PMN-triggered) (NN angiogenesis)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN blocked) (PP (IN by) (NP (CC both) (NP (JJ local) (NN injection)) (CC and) (NP (NP (JJ daily) (RB i.p.) (NN administration)) (PP (IN of) (NP (DT the) (JJ Hyp) (NN salt))) (PP (IN in) (NP (DT an) (JJ interleukin-8-induced) (JJ murine) (NN model))))))))) (. .)))
(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (ADVP (RB i.p.)) (NP (NN treatment)) (PP (IN with) (NP (NN Hyp)))) (VP (VP (VP (VBZ reduces) (NP (JJ acute) (NN PMN) (NN recruitment))) (CC and) (VP (VBZ enhances) (NP (NN resolution)))) (PP (IN in) (NP (DT a) (JJ pulmonary) (JJ bleomycin-induced) (NN inflammation) (NN model))) (, ,) (S (ADVP (RB significantly)) (VP (VBG reducing) (NP (JJ consequent) (NN fibrosis))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NN Hyp)) (VP (VBZ is) (NP (NP (DT a) (JJ powerful) (JJ anti-inflammatory) (NN compound)) (PP (IN with) (NP (JJ therapeutic) (NN potential)))))) (, ,) (CC and) (S (NP (PRP they)) (VP (VBP elucidate) (NP (JJ mechanistic) (NNS keys)))))))) (. .)))
